Insider · CIK 0001678984
Tobin Schilke
cfoofficer
Files at CRNX (Crinetics Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -7,956 | $85.00 | $676k | 71,471 | 41 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -71,471 | $85.00 | $6.1M | 0 | 41 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | $51.25 | $4.1M | 0 | 41 d ago |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | $41.21 | $2.1M | 0 | 41 d ago |
| Mar 10, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | AGrant or award Common Stock | +52,000 | $0.00 | $0 | 52,000 | Mar 11, 2025 |
| Mar 10, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Mar 11, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.